Moderna Inc (MRNA) has a current Price-to-Book (P/B) ratio of 1.29. Compared to its 3-year average P/B ratio of 2.15, the current P/B ratio is approximately -39.74% higher. Relative to its 5-year average P/B ratio of 5.27, the current P/B ratio is about -75.45% higher. Moderna Inc (MRNA) has a Forward Free Cash Flow (FCF) yield of approximately -22.00%. Compared to its 3-year average FCF yield of -16.18%, the current FCF yield is approximately 36.01% lower. Relative to its 5-year average FCF yield of -4.34%, the current FCF yield is about 407.43% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for MRNA competitors is 7.06, providing a benchmark for relative valuation. Moderna Inc Corp (MRNA.O) exhibits a P/S ratio of 6.29, which is -10.8% above the industry average. Given its robust revenue growth of -29.81%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of MRNA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of MRNA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is MRNA currently overvalued or undervalued?

What is Moderna Inc (MRNA) fair value?

MRNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Moderna Inc (MRNA) is between 37.69 to 74.37 according to relative valuation method.

How does MRNA's valuation metrics compare to the industry average?

The average P/S ratio for MRNA's competitors is 7.06, providing a benchmark for relative valuation. Moderna Inc Corp (MRNA) exhibits a P/S ratio of 6.29, which is -10.80% above the industry average. Given its robust revenue growth of -29.81%, this premium appears unsustainable.

What is the current P/B ratio for Moderna Inc (MRNA) as of Mar 02 2026?

As of Mar 02 2026, Moderna Inc (MRNA) has a P/B ratio of 1.29. This indicates that the market values MRNA at 1.29 times its book value.

What is the current FCF Yield for Moderna Inc (MRNA) as of Mar 02 2026?

As of Mar 02 2026, Moderna Inc (MRNA) has a FCF Yield of -22.00%. This means that for every dollar of Moderna Inc's market capitalization, the company generates -22.00 cents in free cash flow.

What is the current Forward P/E ratio for Moderna Inc (MRNA) as of Mar 02 2026?

As of Mar 02 2026, Moderna Inc (MRNA) has a Forward P/E ratio of -3.67. This means the market is willing to pay $-3.67 for every dollar of Moderna Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Moderna Inc (MRNA) as of Mar 02 2026?

As of Mar 02 2026, Moderna Inc (MRNA) has a Forward P/S ratio of 6.29. This means the market is valuing MRNA at $6.29 for every dollar of expected revenue over the next 12 months.

MRNA Valuation